{"id":732731,"date":"2023-02-20T08:03:29","date_gmt":"2023-02-20T13:03:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/"},"modified":"2023-02-20T08:03:29","modified_gmt":"2023-02-20T13:03:29","slug":"esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/","title":{"rendered":"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC"},"content":{"rendered":"

\n\u2013 NEXLETOL\u00ae (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint \u2013
\n<\/h2>\n
\n

ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announces that the landmark C<\/u><\/strong>holesterol L<\/u><\/strong>owering via Be<\/u><\/strong>mpedoic acid, an A<\/u><\/strong>CL-Inhibiting R<\/u><\/strong>egimen (CLEAR) Outcomes trial will be presented as a late-breaking clinical trial at the American College of Cardiology\u2019s Annual Scientific Session Together With the World Congress of Cardiology.<\/p>\n

\u201cSince releasing the positive topline results, we have fielded enthusiastic inquiries from health care providers and scientific leaders, so we are eager to share CLEAR Outcomes data in greater detail,\u201d said Sheldon Koenig, Esperion\u2019s president and chief executive officer. \u201cWe are honored to kick off the Late Breaking Clinical Trial sessions at ACC.23\/WCC and look forward to showcasing the broad cardiovascular risk reduction results that NEXLETOL has demonstrated.\u201d<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n Late Breaking Clinical Trial Presentation<\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
Title:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular\u00a0Outcomes in Statin Intolerant Patients at High Cardiovascular Risk<\/em>\n <\/td>\n<\/tr>\n
Location:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nMain Tent (Great Hall)<\/td>\n<\/tr>\n
Date & Time:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3\/4\/2022, 9:30 \u2013 9:42 AM CST<\/td>\n<\/tr>\n
Speaker:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nSteven Nissen, MD, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n Industry Expert Theatre<\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
Title:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n A Next Step in LDL-C\u2013Lowering Therapy: Oral Nonstatin Therapies<\/em>\n <\/td>\n<\/tr>\n
Location:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nIndustry Expert Theatre #2, Location 2455<\/td>\n<\/tr>\n
Date & Time:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3\/5\/2022, 11:15 AM \u2013 12:15 PM CST<\/td>\n<\/tr>\n
Speaker:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nKausik Ray, BSc (hons), MBChB, FRCP (Lon), FRCP (Ed), MD, MPhil (Cantab), FACC, FESC, FAHA<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n CLEAR Outcomes Late Breaking Clinical Trial Deep Dive \u2013 Session 408<\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
Title:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Bempedoic Acid And Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk<\/em>\n <\/td>\n<\/tr>\n
Location:\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nMain Tent (Great Hall)<\/td>\n<\/tr>\n
Date & Time:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3\/5\/2022, 2:00 \u2013 2:05 PM CST<\/td>\n<\/tr>\n
Speaker:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nSteven Nissen, MD, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic<\/td>\n<\/tr>\n<\/table>\n

\n
\n
INDICATION
<\/strong>NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Limitations of Use<\/em>: The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.<\/p>\n

\n IMPORTANT SAFETY INFORMATION<\/strong>\n <\/p>\n

\n Warnings and Precautions<\/strong>: Hyperuricemia: NEXLETOL may increase blood uric acid levels. Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
Tendon Rupture<\/em>: NEXLETOL is associated with an increased risk of tendon rupture or injury. In clinical trials, tendon rupture occurred in 0.5% of patients treated with NEXLETOL versus 0% of patients treated with placebo, and involved the rotator cuff (the shoulder), biceps tendon, or Achilles tendon. Tendon rupture occurred within weeks to months of starting NEXLETOL. Tendon rupture may occur more frequently in patients over 60 years of age, patients taking corticosteroid or fluoroquinolone drugs, patients with renal failure, and patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Avoid NEXLETOL in patients who have a history of tendon disorders or tendon rupture.<\/p>\n

\n
\n Adverse Reactions<\/em>
\n <\/strong>: In clinical trials, the most commonly reported adverse reactions were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. Reactions reported less frequently, but still more often than with placebo, included benign prostatic hyperplasia and atrial fibrillation.<\/p>\n

\n
\n Drug Interactions<\/em>
\n <\/strong>: Simvastatin and Pravastatin<\/em>: Concomitant use results in increased concentrations and increased risk of simvastatin or pravastatin-related myopathy. Use with greater than 20 mg of simvastatin or 40 mg of pravastatin should be avoided.<\/p>\n

\n
\n Lactation and Pregnancy<\/em>
\n <\/strong>
\n : <\/strong>It is not recommended that NEXLETOL be taken during breastfeeding. Discontinue NEXLETOL when pregnancy is recognized, unless the benefits of therapy outweigh the potential risks to the fetus. Based on the mechanism of action, NEXLETOL may cause fetal harm.<\/p>\n

Please see full Prescribing Information here<\/a>.<\/p>\n

\n Esperion Therapeutics<\/strong>
\n
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol \u2013 that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life\u2019s work. For more information, visit esperion.com<\/u><\/a> and esperionscience.com<\/u><\/a> and follow us on Twitter at twitter.com\/EsperionInc<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding future operations, commercial products and expected growth, clinical development, and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion\u2019s actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our business, revenues, results of operations and financial condition, the net sales, profitability, and growth of Esperion\u2019s commercial products, clinical activities and results, supply chain, commercial development and launch plans, and the risks detailed in Esperion\u2019s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.<\/p>\n

Contact:
Corporate Communications
corporateteam@esperion.com<\/a><\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 NEXLETOL\u00ae (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint \u2013 ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will be presented as a late-breaking clinical trial at the American College of Cardiology\u2019s Annual Scientific Session Together With the World Congress of Cardiology. \u201cSince releasing the positive topline results, we have fielded enthusiastic inquiries from health care providers and scientific leaders, so we are eager to share CLEAR Outcomes data in greater detail,\u201d said Sheldon Koenig, Esperion\u2019s president and chief executive officer. \u201cWe are honored to … <\/p>\n

Continue reading “Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732731","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEsperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 NEXLETOL\u00ae (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint \u2013 ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will be presented as a late-breaking clinical trial at the American College of Cardiology\u2019s Annual Scientific Session Together With the World Congress of Cardiology. \u201cSince releasing the positive topline results, we have fielded enthusiastic inquiries from health care providers and scientific leaders, so we are eager to share CLEAR Outcomes data in greater detail,\u201d said Sheldon Koenig, Esperion\u2019s president and chief executive officer. \u201cWe are honored to … Continue reading "Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-20T13:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\\\/WCC\",\"datePublished\":\"2023-02-20T13:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/\"},\"wordCount\":989,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/\",\"name\":\"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\\\/WCC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=\",\"datePublished\":\"2023-02-20T13:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\\\/WCC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/","og_locale":"en_US","og_type":"article","og_title":"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC - Market Newsdesk","og_description":"\u2013 NEXLETOL\u00ae (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint \u2013 ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will be presented as a late-breaking clinical trial at the American College of Cardiology\u2019s Annual Scientific Session Together With the World Congress of Cardiology. \u201cSince releasing the positive topline results, we have fielded enthusiastic inquiries from health care providers and scientific leaders, so we are eager to share CLEAR Outcomes data in greater detail,\u201d said Sheldon Koenig, Esperion\u2019s president and chief executive officer. \u201cWe are honored to … Continue reading \"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-20T13:03:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC","datePublished":"2023-02-20T13:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/"},"wordCount":989,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/","name":"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=","datePublished":"2023-02-20T13:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MjEyNiM1NDE3MzI0IzIwMDcxNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinical-trial-at-acc-23-wcc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23\/WCC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732731"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732731\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}